The favorable prognostic value of the loss of sex chromosomes in patients with t(8;21) acute myeloid leukemia: an exploratory study. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Zhu, Lixia; Chen, Rongrong; Li, Xueying; Xie, Mixue; Yang, Xiudi; Sun, Jianai; Zhu, Mingyu; Zheng, Xiaolong; Li, Li; Zhu, Jingjing; Zhou, De; Xie, Wanzhuo; Ye, Xiujin
• Is Part Of: Hematology. Volume 27:Issue 1(2022)
• Page Start: 420
• Page End: 425
• Publication Date: 2022-12-31
• Subjects: T(8;21) -- acute myeloid leukemia -- loss of sex chromosome -- -Y -- -X -- additional cytogenetic abnormalities -- disease-free survival -- survival; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1080/16078454.2022.2056982
• Languages: English
• ISSNs: 1024-5332

Abstract

ABSTRACT: Background: Acute myeloid leukemia (AML) with t(8;21) is generally associated with a favorable clinical course. Loss of sex chromosome (LOS) are frequently observed in t (8;21) AML, but the prognostic value of LOS remains uncertain. Methods: A total of 73 patients with AML with t(8;21) were studied and divided into t(8;21) with LOS group ( n = 36) and t(8;21) alone group ( n = 37). The patients with t(8;21) AML with ACAs other than LOS were excluded. The clinical characteristics of these two groups were compared, and the prognostic value of LOS was evaluated based on disease-free survival (DFS) and overall survival (OS). Results: The clinical characteristics (except for gender) were found to have no significant difference between these two groups, and the male patients tended to account for a larger proportion in the former group ( P = .001). The OS of the t(8;21) AML with LOS group was significantly longer than that of the t(8;21) AML alone group ( P = .005). While not obvious, the patients with LOS seemed to have longer DFS ( P = .061). The multivariable analysis also showed LOS to be an independent favorable prognostic factor of t(8;21) AML ( P = .022). Conclusions: Our results suggested that LOS could be associated with a favorable prognosis in t(8;21) AML patients without other ACAs, and for this subtype of AML, longer DFS and a satisfactory and stable survival can be achieved with high-dose cytarabine (HDAC) consolidation treatment.